Mail

Australia markets open in 8 hours 21 minutes

ALL ORDS
7,336.10
+51.00(+0.70%)
AUD/USD
0.6634
-0.0043(-0.65%)
ASX 200
7,124.70
+51.50(+0.73%)
OIL
73.46
-0.61(-0.82%)
GOLD
2,063.70
-26.00(-1.24%)
Bitcoin AUD
62,571.92
+2,757.13(+4.61%)

FEELING THE PINCH?

Beat the cost-of-living squeeze with our pro tips and helpful hacks - sign up now

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

37.90

+1.10

(+2.98%)

As of 09:38AM EST. Market open.

Currency in USD

Valuation measures⁴

Market cap (intra-day)	2.41B
Enterprise value	1.89B
Trailing P/E	N/A
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	N/A
Price/book (mrq)	3.79
Enterprise value/revenue	10.87k
Enterprise value/EBITDA	-9.62

Trading information

Stock price history

Beta (5Y monthly)	1.34
52-week change ³	-5.23%
S&P500 52-week change ³	14.90%
52-week high ³	43.75
52-week low ³	27.99
50-day moving average ³	32.96
200-day moving average ³	36.88

Share statistics

Avg vol (3-month) ³	578.01k
Avg vol (10-day) ³	1.06M
Shares outstanding ⁵	65.43M
Implied shares outstanding ⁶	65.43M
Float ⁸	60.89M
% held by insiders ¹	0.65%
% held by institutions ¹	94.60%
Shares short (14 Nov 2023) ⁴	1.71M
Short ratio (14 Nov 2023) ⁴	2.88
Short % of float (14 Nov 2023) ⁴	2.63%
Short % of shares outstanding (14 Nov 2023) ⁴	2.62%
Shares short (prior month 12 Oct 2023) ⁴	1.96M

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	N/A
Ex-dividend date ⁴	N/A
Last split factor ²	N/A
Last split date ³	N/A

Financial highlights

Fiscal year

Fiscal year ends	30 Dec 2022
Most-recent quarter (mrq)	29 Sept 2023

Profitability

Profit margin	0.00%
Operating margin (ttm)	0.00%

Management effectiveness

Return on assets (ttm)	-17.60%
Return on equity (ttm)	-25.19%

Income statement

Revenue (ttm)	N/A
Revenue per share (ttm)	0.00
Quarterly revenue growth (yoy)	N/A
Gross profit (ttm)	-96.33M
EBITDA	-200.48M
Net income avi to common (ttm)	-175.46M
Diluted EPS (ttm)	-2.66
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	526.67M
Total cash per share (mrq)	8.05
Total debt (mrq)	11M
Total debt/equity (mrq)	1.73%
Current ratio (mrq)	21.46
Book value per share (mrq)	9.79

Cash flow statement

Operating cash flow (ttm)	-142.59M
Levered free cash flow (ttm)	-87.77M